A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
Sponsor: Shanghai Henlius Biotech
Listed as NCT04139135, this PHASE3 trial focuses on Gastric Cancer and remains ongoing. Sponsored by Shanghai Henlius Biotech, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Nov 2024 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Recruiting PHASE3
-
Oct 2021 — Jul 2022 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoding, China , Beijing, China , Bengbu, China , Cangzhou, China , Hefei, China , Linyi, China , Shenzhen, China , Shijia Zhuang, China , Taiyuan, China , Tianjin, China and 1 more location